Arcutis presents positive caregiver-reported outcomes for ZORYVE in infants with AD, supporting label expansion

What happened

Arcutis Biotherapeutics presented new caregiver-reported outcomes data from the INTEGUMENT-INFANT trial at the ACAAI Annual Scientific Meeting, demonstrating improvements in itch, symptoms, and quality of life for infants with atopic dermatitis and their caregivers. The data supports the investigational use of ZORYVE cream 0.05% in infants as young as 3 months with mild-to-moderate atopic dermatitis. Arcutis submitted a supplemental New Drug Application for this indication in April 2026 and is awaiting FDA acceptance. The presentation adds to the company's pediatric expansion narrative, complementing the upcoming June 29, 2026 PDUFA date for pediatric psoriasis. While positive, the news is incremental and does not alter near-term financial projections or regulatory timelines.

Implication

For investors, the new caregiver-reported outcomes reinforce the long-term growth optionality in pediatric dermatology, but the infant AD indication is not yet approved and will likely not contribute meaningfully to revenue until 2027 or later. The more immediate catalyst remains the FDA decision on pediatric psoriasis scheduled for June 29, 2026. This news may provide a slight sentiment boost but should not change the fundamental valuation models. Key watch items include FDA acceptance of the infant AD sNDA and continued prescription growth and positive cash flow. Overall, the thesis remains intact, and investors should focus on the Q2 revenue re-acceleration and operating cash flow sustainability.

Thesis delta

The thesis remains unchanged: investors should monitor Q2'26 net product revenue re-acceleration and the June 29 pediatric psoriasis FDA decision. The infant AD data is a minor positive that supports the long-term pediatric franchise narrative but does not shift the base/bear/bull scenarios. No adjustments to valuation or risk assessment are warranted at this time.